フィルター
6 件の結果が “961” で取得されました
並べ替える:
アルファベット順（A-Z）
ベストセラー
B6-hCD47
製品ID :
C001419
系統:
C57BL/6JCya
状況:
説明:
CD47, also known as Integrin Associated Protein (IAP), is a transmembrane protein that belongs to the immunoglobulin superfamily. It is widely expressed on the surface of almost all normal cells and is highly expressed in tumor cells [1].
SIRPα, a signal regulatory protein mainly expressed on macrophages, inhibits their phagocytosis of target cells by transmitting inhibitory signals when binding to CD47 on other cells. However, some tumor cells can evade phagocytosis and cause tumor immune escape by highly expressing CD47 and binding to SIRPα on macrophages, sending a “don’t eat me” signal. Targeting CD47 antibodies can initiate anti-tumor T cell immune responses and promote cancer-specific lymphocyte activation through macrophage-mediated phagocytosis of tumors. As a result, the CD47-SIRPα signaling pathway has great therapeutic potential and is a highly competitive target in tumor immunotherapy after PD-1/PD-L1 [1-2].
CD47 is a transmembrane protein with its extracellular domain serving as the receptor/ligand binding region and its intracellular domain responsible for signal transduction [3]. B6-hCD47 mice are obtained by replacing the fragment encoding the extracellular domain of CD47 protein in the mouse Cd47 gene with the corresponding human CD47 gene sequence, resulting in a model expressing the extracellular domain of human CD47 protein and the intracellular domain of mouse CD47 protein. This ensures normal binding with human antibodies and other protein drugs while completely retaining the intracellular part of mouse CD47 protein, maintaining normal intracellular signal transduction. B6-hCD47 mice can successfully express human CD47 protein and can be used for research on CD47-targeted inhibitors or antibody drug development and screening, pharmacology and safety evaluation, tumor immunotherapy evaluation, and mechanisms of tumor immune escape systems.
CD47, also known as Integrin Associated Protein (IAP), is a transmembrane protein that belongs to the immunoglobulin superfamily. It is widely expressed on the surface of almost all normal cells and is highly expressed in tumor cells [1].
SIRPα, a signal regulatory protein mainly expressed on macrophages, inhibits their phagocytosis of target cells by transmitting inhibitory signals when binding to CD47 on other cells. However, some tumor cells can evade phagocytosis and cause tumor immune escape by highly expressing CD47 and binding to SIRPα on macrophages, sending a “don’t eat me” signal. Targeting CD47 antibodies can initiate anti-tumor T cell immune responses and promote cancer-specific lymphocyte activation through macrophage-mediated phagocytosis of tumors. As a result, the CD47-SIRPα signaling pathway has great therapeutic potential and is a highly competitive target in tumor immunotherapy after PD-1/PD-L1 [1-2].
CD47 is a transmembrane protein with its extracellular domain serving as the receptor/ligand binding region and its intracellular domain responsible for signal transduction [3]. B6-hCD47 mice are obtained by replacing the fragment encoding the extracellular domain of CD47 protein in the mouse Cd47 gene with the corresponding human CD47 gene sequence, resulting in a model expressing the extracellular domain of human CD47 protein and the intracellular domain of mouse CD47 protein. This ensures normal binding with human antibodies and other protein drugs while completely retaining the intracellular part of mouse CD47 protein, maintaining normal intracellular signal transduction. B6-hCD47 mice can successfully express human CD47 protein and can be used for research on CD47-targeted inhibitors or antibody drug development and screening, pharmacology and safety evaluation, tumor immunotherapy evaluation, and mechanisms of tumor immune escape systems.
huUSH2A(E10-15)-c.2286_2287insT
製品ID :
C001961
系統:
C57BL/6JCya
状況:
説明:
The USH2A gene encodes Usherin, a protein featuring laminin EGF-like, pentraxin, and fibronectin type III domains, predominantly expressed in the basement membrane of the inner ear and retina. Usherin plays a critical role in developing hair cells in the inner ear, auditory signal transduction, and the maintenance of adhesion via interactions with fibronectin in the retinal basement membrane. Mutations in the USH2A gene disrupt the normal development and function of hair cells, impair fibronectin assembly, and compromise the adhesive properties of the retinal basement membrane, leading to hearing loss and RP symptoms. The USH2A gene is the primary causative gene for Usher syndrome Type II (USH2), with 75%–90% of USH2 cases linked to mutations in this gene [1]. The mutations mainly cause frameshift and premature termination codons, producing a protein that is 85% truncated compared to the normal transcript size, leading to the loss of Usherin protein function [2-5]. Currently, there are no effective therapies for Usher syndrome. Ongoing research focuses on elucidating the genetic mechanisms underlying the disorder and developing gene-based therapeutic strategies.
huUSH2A(E10-15)-c.2286_2287insT mice are obtained by introducing the c.2286_2287insT mutation into the exon 13 of the human USH2A gene in huUSH2A(E10-15) mice (Catalog Number: C001554) using gene editing technology. This model can be used to study the mechanisms and therapeutic approaches for diseases such as Usher syndrome Type II.
The USH2A gene encodes Usherin, a protein featuring laminin EGF-like, pentraxin, and fibronectin type III domains, predominantly expressed in the basement membrane of the inner ear and retina. Usherin plays a critical role in developing hair cells in the inner ear, auditory signal transduction, and the maintenance of adhesion via interactions with fibronectin in the retinal basement membrane. Mutations in the USH2A gene disrupt the normal development and function of hair cells, impair fibronectin assembly, and compromise the adhesive properties of the retinal basement membrane, leading to hearing loss and RP symptoms. The USH2A gene is the primary causative gene for Usher syndrome Type II (USH2), with 75%–90% of USH2 cases linked to mutations in this gene [1]. The mutations mainly cause frameshift and premature termination codons, producing a protein that is 85% truncated compared to the normal transcript size, leading to the loss of Usherin protein function [2-5]. Currently, there are no effective therapies for Usher syndrome. Ongoing research focuses on elucidating the genetic mechanisms underlying the disorder and developing gene-based therapeutic strategies.
huUSH2A(E10-15)-c.2286_2287insT mice are obtained by introducing the c.2286_2287insT mutation into the exon 13 of the human USH2A gene in huUSH2A(E10-15) mice (Catalog Number: C001554) using gene editing technology. This model can be used to study the mechanisms and therapeutic approaches for diseases such as Usher syndrome Type II.
Agtrap-KO
製品ID :
S-KO-00961
系統:
C57BL/6JCya
状況:
説明:
Agtrap is located on chromosome 4 of mice. Nuclease Technology was used to design sgRNA; Agtrap knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Agtrap is located on chromosome 4 of mice. Nuclease Technology was used to design sgRNA; Agtrap knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Ace-flox
製品ID :
S-CKO-00961
系統:
C57BL/6JCya
状況:
説明:
Ace is located on chromosome 11 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Ace conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Ace is located on chromosome 11 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Ace conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp961-KO
製品ID :
S-KO-06715
系統:
C57BL/6JCya
状況:
説明:
Zfp961 is located on chromosome 8 of mice. Nuclease Technology will be used to design sgRNA; Zfp961 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp961 is located on chromosome 8 of mice. Nuclease Technology will be used to design sgRNA; Zfp961 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp961-flox
製品ID :
S-CKO-07737
系統:
C57BL/6JCya
状況:
説明:
Zfp961 is located on chromosome 8 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Zfp961 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Zfp961 is located on chromosome 8 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Zfp961 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Items: 1 to 6 of 6
1